title: [The use of ergonovine in the hemodynamics laboratory].
abstract: In our department we have reviewed the use of ergonovine maleate as a provocative agent for inducing coronary spasm during coronary arteriography. From January 1978 to December 1991 the test has been performed in 116 patients. According to their symptoms, the patients were divided into 4 groups: (A) patients with exertional angina: 16 patients (13.8%), (B) patients with angina at rest: 64 patients (55.2%), (C) patients with atypical chest pain: 29 patients (25%), and (D) patients with previous myocardial infarct: 7 patients (6%). We have subdivided the patients with angina at rest, according to the electrocardiogram recorded during pain, into: (1) 16 patients with ST-segment elevation; (2) 14 patients with ST-segment depression or T wave inversion; (3) 5 patients with electrocardiogram unchanged during angina; (4) 29 patients with no electrocardiogram recorded during angina. In 67 patients (57.7%) the coronaries were normal, 17 patients (14.6%) had mild irregularities, 26 patients (22.4%) had non critical fixed obstructions (< or = 70%), and in 6 patients (3.5%) there were fixed coronary narrowings > or = 70%. The left ventricle was normal in 85 subjects (73.2%), hypo or akinetic in 31 (26.8%). After routine coronary angiography and ventriculography, ergonovine maleate, 0.05 up to 0.4 mg, was given intravenously. The ergonovine test was considered positive when a focal spasm narrowed a normal coronary artery, or one with a mild fixed obstruction (< or = 50%) to more than 70%, or when a 70% stenosis became occluded. The development of angina and/or electrocardiographic changes were not taken as a criteria of positivity. Thirteen tests (11.2%) were considered positive.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Istituto di Medicina e Chirurgia Cardiovascolare, Università degli Studi di Torino.
authors.forename: P
authors.initials: P
authors.lastname: Carvalho
authors.forename: S
authors.initials: S
authors.lastname: Grossi
authors.forename: F
authors.initials: F
authors.lastname: Orzan
authors.forename: A
authors.initials: A
authors.lastname: Brusca
mesh_terms: D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology; D000788:Angina Pectoris, Variant / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology; D017023:Coronary Angiography; D004562:Electrocardiography / Q000187:drug effects; D004874:Ergonovine / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D015994:Incidence; D007558:Italy / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology; D005082:Physical Exertion; D012189:Retrospective Studies
chemical_list: D004874:Ergonovine
vernacular_title: L'uso della ergonovina nel laboratorio di emodinamica.